Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13385643 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL1535502 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL14769719 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950236 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21448801 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950131 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950441 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950237 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL14769720 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL8895624 | 1.00 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000469-B1 | STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIV RAMON Y CAJAL (ES) | 2019-03-13 | — | — | EP | claimed |
| CN-108026131-A | POLYMER-CYCLODEXTRIN-LIPID CONJUGATES | 吴念 | 2018-05-11 | — | — | CN | claimed |
| US-20230357140-A1 | TES-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210346507-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-10-21 | — | — | US | disclosed |
| US-10947271-B2 | Antibacterial agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-16 | — | — | US | disclosed |
| WO-2020061284-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | NIRSUM LABORATORIES, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190308989-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190307743-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | ONCOTHYREON INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8097593-B1 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1549322-B1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-1997030950-A1 | IMPROVED ORGANOCLAY COMPOSITIONS | SOUTHERN CLAY PRODUCTS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | SELPLG, STT3A, LY96 | CES2 2057/4885MEN1 4478/4885FAAH 1131/4885 |
| US-20190308989-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | CES2 241/4885MEN1 4879/4885FAAH 239/4885 |
| US-20190307743-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRM1, OPRK1, OPRL1 | CES2 241/4885MEN1 4879/4885FAAH 239/4885 |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | CES2 2830/4885MEN1 2740/4885FAAH 3969/4885 |
| US-10544154-B2 | Opioid receptor antagonist prodrugs | OPRM1, OPRK1, OPRL1 | CES2 241/4885MEN1 4879/4885FAAH 239/4885 |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | DCTD, MTAP, ADA | CES2 73/4885MEN1 4076/4885FAAH 2357/4885 |
| US-20230357140-A1 | TES-BASED CATIONIC LIPIDS | CETP, NPC1L1, NPC1 | CES2 326/4885MEN1 1645/4885FAAH 3353/4885 |
| US-20120219617-A1 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | MUC1, LGALS3BP, ST3GAL3 | CES2 4767/4885MEN1 670/4885FAAH 2195/4885 |
| US-10947271-B2 | Antibacterial agents | VNN1, ASNS, AAAS | CES2 3149/4885MEN1 3291/4885FAAH 2442/4885 |
| US-20210346507-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | CES2 2830/4885MEN1 2740/4885FAAH 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.